Compugen (XTAE:CGEN) Insider Ownership : 0.00 % (As of May. 11, 2025)

View and export this data going back to 2002. Start your Free Trial

What is Compugen Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Compugen's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Compugen's Institutional Ownership is 4.25%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Compugen's Float Percentage Of Total Shares Outstanding is 96.78%.

Compugen Insider Ownership Historical Data

The historical data trend for Compugen's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen Insider Ownership Chart

Compugen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Insider Ownership

Get a 7-Day Free Trial

Compugen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Insider Ownership	Get a 7-Day Free Trial															-	-	-	-	-

Compugen Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Compugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (XTAE:CGEN) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

CGEN:USA

Address

26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849

Website

https://www.cgen.com

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.